Quick Answer
ACRO BIOMEDICAL CO., LTD. reported Diluted EPS of $0.00 per share for fiscal year 2025.
ACRO BIOMEDICAL CO., LTD. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $0.00 | — |
| 2024 | $0.00 | +100.0% |
| 2023 | -$0.15 | +42.3% |
| 2022 | -$0.26 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.00 | — | — |
| June 30, 2025 | $0.00 | — | — |
| March 31, 2025 | $0.00 | — | — |
| September 30, 2024 | $0.00 | +100.0% | — |
| June 30, 2024 | $0.00 | +100.0% | — |
| March 31, 2024 | $0.00 | +100.0% | +100.0% |
| September 30, 2023 | -$0.03 | +57.1% | +40.0% |
| June 30, 2023 | -$0.05 | — | +28.6% |
- Over the 2022–2025 period, ACRO BIOMEDICAL CO., LTD.’s diluted eps has grown by 100.0% (from $0.26 per share (loss) to $0.00 per share).
- The most recent figure is from ACRO BIOMEDICAL CO., LTD.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: